Duncan McHale

Chief Medical Officer at Evelo Biosciences, Inc.

Duncan McHale

Duncan McHale

Chief Medical Officer at Evelo Biosciences, Inc.

Biography

Duncan McHale, M.B.B.S., Ph.D. has served as our Chief Medical Officer since February 2018. From September 2011 to May 2017, Dr. McHale served as the Head of Global Exploratory Development at UCB S.A. Prior to that, he was Vice President and Head Translational Sciences for AstraZeneca and Executive Director and Head Translational Molecular Medicine for Pfizer UK. He is currently the Chair of the UK Medical Research Councils Stratified Medicines Governance Committee. Dr. McHale received his M.B.B.S. from Newcastle University and his Ph.D. in Clinical Genetics from the University of Leeds.

Overview
RelSci Relationships

19

Birthday

1967

Age

53

Relationships
RelSci Relationships are individuals Duncan McHale likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Moderna, Inc.

Relationship likelihood: Strong

Founding Member at Evelo Biosciences, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Evelo Biosciences, Inc.

Relationship likelihood: Strong

Former Founding Member at Evelo Biosciences, Inc.

Relationship likelihood: Strong

General Counsel & Secretary at Evelo Biosciences, Inc.

Relationship likelihood: Strong

Secretary & General Counsel at Morphic Holding, Inc.

Relationship likelihood: Average

Former Senior Vice President at Shire Plc (Inactive)

Relationship likelihood: Average

Vice President Program Direction at Regeneron Pharmaceuticals, Inc.

Relationship likelihood: Average

Chief People Officer at Evelo Biosciences, Inc.

Relationship likelihood: Average

Global Head of Regulatory Affairs, EU Head of Clinical Development at Evelo Biosciences, Inc.

Relationship likelihood: Average

Paths to Duncan McHale
Potential Connections via
Relationship Science
You
Duncan McHale
Chief Medical Officer at Evelo Biosciences, Inc.
Career History
Chief Medical Officer
2018 - Current

Evelo Biosciences, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of monoclonal microbials, a modality of oral biologic medicines. It has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.

Transactions
Details Hidden

Evelo Biosciences, Inc. raised money in a private placement transaction

Details Hidden

Evelo Biosciences, Inc. raised money in a private placement transaction

Other Affiliations

Duncan McHale is affiliated with Evelo Biosciences, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Duncan McHale. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Duncan McHale's profile does not indicate a business or promotional relationship of any kind between RelSci and Duncan McHale.